The Supreme Court declined to take up lawsuits challenging Medicare drug price negotiations, dealing another blow to the brand-drug industry’s legal strategy. The decision affects cases filed by AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Novo Nordisk, according to the report. Separately, a related coverage piece reiterates that the Court also won’t review the broader IRA pricing litigation, confirming the current legal posture for the negotiated pricing program and limiting near-term avenues for reversal at the highest level.